JP2019081792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019081792A5 JP2019081792A5 JP2019034250A JP2019034250A JP2019081792A5 JP 2019081792 A5 JP2019081792 A5 JP 2019081792A5 JP 2019034250 A JP2019034250 A JP 2019034250A JP 2019034250 A JP2019034250 A JP 2019034250A JP 2019081792 A5 JP2019081792 A5 JP 2019081792A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acetate
- cellulose
- hydroxypropylmethylcellulose
- polyvinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- -1 4 - ([1,2,4] triazolo [1,5-a] pyridin-7-yloxy) -3-methylphenyl Chemical group 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 229920002678 cellulose Polymers 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- 229920002301 cellulose acetate Polymers 0.000 claims 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims 4
- 239000011118 polyvinyl acetate Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 235000010981 methylcellulose Nutrition 0.000 claims 3
- RNWDENXDCQXZLH-UHFFFAOYSA-N quinazoline-4,6-diamine Chemical compound N1=CN=C(N)C2=CC(N)=CC=C21 RNWDENXDCQXZLH-UHFFFAOYSA-N 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 239000004698 Polyethylene Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 2
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 claims 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 2
- 229920001400 block copolymer Polymers 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920000578 graft copolymer Polymers 0.000 claims 2
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229920000573 polyethylene Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000005591 trimellitate group Chemical group 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000004815 dispersion polymer Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 229960002014 ixabepilone Drugs 0.000 claims 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000013538 segmental resection Methods 0.000 claims 1
- 210000005005 sentinel lymph node Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021097676A JP2021178820A (ja) | 2012-03-23 | 2021-06-11 | 脳癌の治療 |
| JP2022177278A JP7404485B2 (ja) | 2012-03-23 | 2022-11-04 | 脳癌の治療 |
| JP2023209972A JP2024019526A (ja) | 2012-03-23 | 2023-12-13 | 脳癌の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615082P | 2012-03-23 | 2012-03-23 | |
| US61/615,082 | 2012-03-23 | ||
| JP2017103957A JP2017141302A (ja) | 2012-03-23 | 2017-05-25 | 脳癌の治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017103957A Division JP2017141302A (ja) | 2012-03-23 | 2017-05-25 | 脳癌の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021097676A Division JP2021178820A (ja) | 2012-03-23 | 2021-06-11 | 脳癌の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019081792A JP2019081792A (ja) | 2019-05-30 |
| JP2019081792A5 true JP2019081792A5 (https=) | 2019-12-12 |
| JP6898960B2 JP6898960B2 (ja) | 2021-07-07 |
Family
ID=48048296
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501952A Pending JP2015514075A (ja) | 2012-03-23 | 2013-03-25 | 脳癌の治療 |
| JP2017103957A Pending JP2017141302A (ja) | 2012-03-23 | 2017-05-25 | 脳癌の治療 |
| JP2019034250A Active JP6898960B2 (ja) | 2012-03-23 | 2019-02-27 | 脳癌の治療 |
| JP2021097676A Pending JP2021178820A (ja) | 2012-03-23 | 2021-06-11 | 脳癌の治療 |
| JP2022177278A Active JP7404485B2 (ja) | 2012-03-23 | 2022-11-04 | 脳癌の治療 |
| JP2023209972A Pending JP2024019526A (ja) | 2012-03-23 | 2023-12-13 | 脳癌の治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501952A Pending JP2015514075A (ja) | 2012-03-23 | 2013-03-25 | 脳癌の治療 |
| JP2017103957A Pending JP2017141302A (ja) | 2012-03-23 | 2017-05-25 | 脳癌の治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021097676A Pending JP2021178820A (ja) | 2012-03-23 | 2021-06-11 | 脳癌の治療 |
| JP2022177278A Active JP7404485B2 (ja) | 2012-03-23 | 2022-11-04 | 脳癌の治療 |
| JP2023209972A Pending JP2024019526A (ja) | 2012-03-23 | 2023-12-13 | 脳癌の治療 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150110780A1 (https=) |
| EP (4) | EP4252855A3 (https=) |
| JP (6) | JP2015514075A (https=) |
| KR (3) | KR102490961B1 (https=) |
| CN (2) | CN104203279B (https=) |
| AU (4) | AU2013234921A1 (https=) |
| CA (1) | CA2867723C (https=) |
| CL (1) | CL2014002497A1 (https=) |
| CO (1) | CO7071139A2 (https=) |
| CY (2) | CY1120204T1 (https=) |
| DK (2) | DK3400943T3 (https=) |
| ES (2) | ES2673165T3 (https=) |
| HR (1) | HRP20180659T1 (https=) |
| HU (2) | HUE053156T2 (https=) |
| IL (3) | IL234627B (https=) |
| LT (1) | LT2827900T (https=) |
| MX (1) | MX354024B (https=) |
| MY (2) | MY202114A (https=) |
| NZ (4) | NZ630843A (https=) |
| PH (2) | PH12021550360A1 (https=) |
| PL (2) | PL3400943T3 (https=) |
| PT (2) | PT2827900T (https=) |
| RS (1) | RS57140B1 (https=) |
| RU (2) | RU2672575C2 (https=) |
| SG (1) | SG11201405954YA (https=) |
| SI (2) | SI2827900T1 (https=) |
| SM (1) | SMT201800251T1 (https=) |
| TR (1) | TR201808450T4 (https=) |
| UA (1) | UA122044C2 (https=) |
| WO (1) | WO2013142875A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2629116C2 (ru) | 2011-10-14 | 2017-08-24 | Эррэй Биофарма Инк. | Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их |
| BR122020010643B1 (pt) | 2011-10-14 | 2022-05-17 | Array Biopharma Inc | Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida |
| WO2013142875A1 (en) | 2012-03-23 | 2013-09-26 | Array Biopharma Inc. | Treatment of brain cancer |
| US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
| CA3060407A1 (en) | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| US11298422B2 (en) * | 2018-04-09 | 2022-04-12 | Novocure Gmbh | Treating tumors with TTFields and an aurora kinase inhibitor |
| CN109942576B (zh) * | 2019-03-07 | 2020-09-11 | 上海工程技术大学 | Irbinitinib及中间体的制备方法 |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| CN111825604A (zh) * | 2019-04-16 | 2020-10-27 | 宁波药腾医药科技有限公司 | 一种图卡替尼及其中间产物的合成方法 |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH690163A5 (fr) * | 1995-07-28 | 2000-05-31 | Symphar Sa | Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers. |
| US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| RU2255765C2 (ru) * | 2000-01-21 | 2005-07-10 | Чилдренз Хоспитал Лос-Анджелес | Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов |
| WO2001091794A2 (en) | 2000-05-30 | 2001-12-06 | Virginia Commonwealth University | Vitamin d3 analogs as radiosensitizers for the treatment of cancer |
| WO2005016346A1 (en) | 2003-08-14 | 2005-02-24 | Array Biopharma Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| CN1989112A (zh) * | 2004-06-03 | 2007-06-27 | 史密丝克莱恩比彻姆（科克）有限公司 | 癌症治疗方法 |
| BRPI0511754A (pt) | 2004-06-03 | 2008-01-02 | Smithkline Beechman Cork Ltd | uso de um composto ou sais ou solvatos do mesmo |
| ES2364901T3 (es) | 2005-11-15 | 2011-09-16 | Array Biopharma, Inc. | Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina. |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| CA2700673A1 (en) * | 2007-09-24 | 2009-04-02 | Tragara Pharmaceuticals, Inc. | Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors |
| NZ602675A (en) | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| RU2629116C2 (ru) | 2011-10-14 | 2017-08-24 | Эррэй Биофарма Инк. | Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их |
| BR122020010643B1 (pt) | 2011-10-14 | 2022-05-17 | Array Biopharma Inc | Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida |
| WO2013142875A1 (en) | 2012-03-23 | 2013-09-26 | Array Biopharma Inc. | Treatment of brain cancer |
-
2013
- 2013-03-25 WO PCT/US2013/033751 patent/WO2013142875A1/en not_active Ceased
- 2013-03-25 PL PL18162971T patent/PL3400943T3/pl unknown
- 2013-03-25 HU HUE18162971A patent/HUE053156T2/hu unknown
- 2013-03-25 PT PT137144978T patent/PT2827900T/pt unknown
- 2013-03-25 PH PH1/2021/550360A patent/PH12021550360A1/en unknown
- 2013-03-25 EP EP23163332.2A patent/EP4252855A3/en not_active Withdrawn
- 2013-03-25 EP EP20210661.3A patent/EP3842044A1/en not_active Withdrawn
- 2013-03-25 DK DK18162971.8T patent/DK3400943T3/da active
- 2013-03-25 EP EP13714497.8A patent/EP2827900B1/en active Active
- 2013-03-25 CN CN201380015856.XA patent/CN104203279B/zh active Active
- 2013-03-25 RS RS20180484A patent/RS57140B1/sr unknown
- 2013-03-25 KR KR1020217033686A patent/KR102490961B1/ko active Active
- 2013-03-25 ES ES13714497.8T patent/ES2673165T3/es active Active
- 2013-03-25 JP JP2015501952A patent/JP2015514075A/ja active Pending
- 2013-03-25 US US14/387,533 patent/US20150110780A1/en not_active Abandoned
- 2013-03-25 NZ NZ630843A patent/NZ630843A/en unknown
- 2013-03-25 DK DK13714497.8T patent/DK2827900T3/en active
- 2013-03-25 SG SG11201405954YA patent/SG11201405954YA/en unknown
- 2013-03-25 SM SM20180251T patent/SMT201800251T1/it unknown
- 2013-03-25 TR TR2018/08450T patent/TR201808450T4/tr unknown
- 2013-03-25 PL PL13714497T patent/PL2827900T3/pl unknown
- 2013-03-25 RU RU2014142700A patent/RU2672575C2/ru active
- 2013-03-25 MY MYPI2019003395A patent/MY202114A/en unknown
- 2013-03-25 AU AU2013234921A patent/AU2013234921A1/en not_active Abandoned
- 2013-03-25 MX MX2014011437A patent/MX354024B/es active IP Right Grant
- 2013-03-25 NZ NZ756264A patent/NZ756264A/en unknown
- 2013-03-25 EP EP18162971.8A patent/EP3400943B1/en not_active Revoked
- 2013-03-25 KR KR1020147029340A patent/KR102160462B1/ko active Active
- 2013-03-25 HU HUE13714497A patent/HUE037966T2/hu unknown
- 2013-03-25 RU RU2018138976A patent/RU2018138976A/ru unknown
- 2013-03-25 SI SI201331019T patent/SI2827900T1/en unknown
- 2013-03-25 HR HRP20180659TT patent/HRP20180659T1/hr unknown
- 2013-03-25 KR KR1020207027176A patent/KR102317166B1/ko active Active
- 2013-03-25 NZ NZ74161513A patent/NZ741615A/en unknown
- 2013-03-25 LT LTEP13714497.8T patent/LT2827900T/lt unknown
- 2013-03-25 CA CA2867723A patent/CA2867723C/en active Active
- 2013-03-25 NZ NZ724544A patent/NZ724544A/en unknown
- 2013-03-25 UA UAA201411479A patent/UA122044C2/uk unknown
- 2013-03-25 PT PT181629718T patent/PT3400943T/pt unknown
- 2013-03-25 MY MYPI2014702686A patent/MY174883A/en unknown
- 2013-03-25 ES ES18162971T patent/ES2855142T3/es active Active
- 2013-03-25 SI SI201331844T patent/SI3400943T1/sl unknown
- 2013-03-25 CN CN201811150918.9A patent/CN109223791A/zh active Pending
-
2014
- 2014-09-12 PH PH12014502032A patent/PH12014502032A1/en unknown
- 2014-09-14 IL IL234627A patent/IL234627B/en active IP Right Grant
- 2014-09-19 CO CO14208829A patent/CO7071139A2/es unknown
- 2014-09-22 CL CL2014002497A patent/CL2014002497A1/es unknown
-
2017
- 2017-05-25 JP JP2017103957A patent/JP2017141302A/ja active Pending
- 2017-12-06 AU AU2017272232A patent/AU2017272232C1/en active Active
-
2018
- 2018-05-14 CY CY20181100493T patent/CY1120204T1/el unknown
- 2018-09-06 IL IL261659A patent/IL261659A/en unknown
-
2019
- 2019-02-27 JP JP2019034250A patent/JP6898960B2/ja active Active
- 2019-05-02 US US16/402,068 patent/US11504370B2/en active Active
- 2019-05-23 AU AU2019203618A patent/AU2019203618B2/en active Active
- 2019-09-09 IL IL269205A patent/IL269205B/en active IP Right Grant
-
2021
- 2021-02-16 CY CY20211100126T patent/CY1123837T1/el unknown
- 2021-06-11 JP JP2021097676A patent/JP2021178820A/ja active Pending
- 2021-11-01 AU AU2021261849A patent/AU2021261849A1/en not_active Abandoned
-
2022
- 2022-10-28 US US17/975,709 patent/US20230190749A1/en active Pending
- 2022-11-04 JP JP2022177278A patent/JP7404485B2/ja active Active
-
2023
- 2023-12-13 JP JP2023209972A patent/JP2024019526A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019081792A5 (https=) | ||
| JP6770157B2 (ja) | 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物 | |
| ES2693686T3 (es) | Formulaciones de comprimidos de liberación inmediata | |
| HRP20231699T1 (hr) | Formulacije inhibitora amorfne kinaze i postupci njihove primjene | |
| JP6606279B2 (ja) | 適用部位における滞留時間が改善された、電気流体力学的に得られた繊維を含む医薬組成物 | |
| JP2024019526A (ja) | 脳癌の治療 | |
| CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| KR20170057435A (ko) | 궤양성 대장염의 치료용 의약 조성물 | |
| US20170333404A1 (en) | Improved formulations of vemurafenib and methods of making the same | |
| JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
| JPWO2021138483A5 (https=) | ||
| JP2023175825A (ja) | 肝細胞癌の治療のための併用療法 | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| CN104338147B (zh) | 一种用于缓控释给药的软膏组合基质 | |
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| JP7372740B2 (ja) | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ | |
| CN1414847A (zh) | 含吡喹酮的缓释抗蠕虫组合物 | |
| US8236814B2 (en) | Composition and method for treatment of warts | |
| WO2022166778A1 (zh) | 一种衣壳蛋白抑制剂的药物组合物及其制备方法 | |
| CN101647954B (zh) | 一种用于治疗宫颈炎的中药膜剂及其制备方法和应用 | |
| US20250255822A1 (en) | Triptolide formulations | |
| AU2016280148A1 (en) | Extended release Capecitabine capsules | |
| CN106038566B (zh) | 一种用于胃癌治疗的药物组合物及其应用 | |
| CN100441201C (zh) | 含积雪草水溶性有效组分的中药缓释制剂及其制备方法 | |
| CN103142659A (zh) | 一种含白葡奈氏菌的膜包衣片剂 |